Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, has officially submitted its IPO application to the Hong Kong Stock Exchange on November 29. The company, known for its robust pipeline of 12 innovative candidate drugs, has six of which have already entered clinical trial stages.
Core Product LBL-024: A Dual-Targeting Bispecific Antibody
Particularly noteworthy is the company’s core product, LBL-024, a novel bispecific antibody targeting PD-L1 and 4-1BB, which is currently in pivotal clinical trials. This therapy has shown preliminary efficacy in treating solid tumors and autoimmune diseases, with an objective response rate (ORR) of 18% and a disease control rate (DCR) of 41%.
Strategic Partnerships and Licensing Agreements
Nanjing Leads Biolabs has made significant strides in new drug licensing cooperation, securing a deal with BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) worth up to USD 772 million for the rights to the anti-LAG-3 antibody LBL-007. Additionally, the company signed a USD 614 million NewCo cooperation agreement with Aditum Bio for the CD19xBCMAxCD3 trispecific T-cell engager antibody LBL-051.
Commitment to Independent Innovation and Global Collaboration
The company is dedicated to the independent discovery, development, and commercialization of novel tumor immunotherapies. Utilizing its proprietary bispecific antibody and other technology platforms, Nanjing Leads Biolabs focuses on T cell-centric immunotherapies. The company leverages a deep understanding of T cell immunity, multi-dimensional antibody engineering, and comprehensive disease biology to address the challenges in developing new target drugs, designing molecules that can stimulate potent anti-tumor activity while reducing the risk of adverse events.
Global Clinical Resources and Pipeline Diversity
Nanjing Leads Biolabs collaborates with leading pharmaceutical companies and investment institutions worldwide, efficiently utilizing international clinical resources to accelerate the global development of its drugs. The company’s pipeline includes three monoclonal antibodies for tumors, four bispecific antibodies, two antibody-drug conjugates (ADCs), one bispecific fusion protein for tumors, and one bispecific fusion protein and one trispecific antibody for autoimmune diseases.-Fineline Info & Tech
